Be6A Lung-01: This clinical trial is being done to see if an antibody drug conjugate (called sigvotatug vedotin) works better than chemotherapy (called docetaxel) in people with metastatic or advanced non-small cell lung cancer who have had prior treatmentA Randomized, Phase 3, Open-label Study to Evaluate SGN-B6A Compared With Docetaxel in Adult Subjects With Previously Treated Non-small Cell Lung Cancer

Exclusion

• Life expectancy of less than (<) 3 months
• Known allergies/hypersensitivity/intolerance to or contraindication of taxanes, docetaxel, or any excipient contained in the drug formulation of sigvotatug vedotin
• History of another malignancy within 3 years before Cycle 1 Day 1, or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death

• Participants with any of the following respiratory conditions:

  • Evidence of noninfectious interstitial lung disease (ILD) or pneumonitis that:

    • Was previous diagnosed and required systemic steroids, or
    • Is currently diagnosed and managed, or
    • Is suspected on radiologic imaging at screening
  • Known diffusing capacity of the lung for carbon monoxide (DLCO) < 50%
  • Any Grade greater than or equal to (≥) 3 pulmonary disease unrelated to underlying malignancy
• Pre-existing peripheral neuropathy Grade greater than or equal to (≥) 2
• Uncontrolled diabetes mellitus

• Prior therapy:

  • Prior treatment with antimicrotubule agents (taxanes, vinca alkaloids, or MMAEs) in the locally advanced, unresectable, or metastatic setting
  • Received more than 1 prior line of cytotoxic chemotherapy in the locally advanced, unresectable, or metastatic setting
  • At least 14 days must have elapsed from the last dose of radiotherapy until Cycle 1 Day 1.
  • Prior radiation therapy to the lung parenchyma that is >30 Gray (Gy) within 6 months of Cycle 1 Day 1.
  • Any systemic anticancer therapy (standard or experimental) within 21 days prior to Cycle 1 Day 1.

• Active central nervous system (CNS) lesions, including leptomeningeal metastasis, are excluded. Participants with definitively treated brain metastases are eligible in they meet the following criteria:

  • Have been clinically stable for at least 4 weeks prior to treatment initiation and baseline scans show no evidence of new or enlarged metastasis
  • On a stable dose of less than or equal to (≤) 10mg/day of prednisone or equivalent for a least 2 weeks (if requiring steroid treatment)
  • Treatment with corticosteroids greater than (>) 1 month prior to Screening visit
  • No evidence of clinical and radiographic disease progression in the CNS for ≥ 21 days after definitive radiotherapy and/or surgery